The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to:
Our novel technology provides an unprecedented technical advancement in ocular drug formulation, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
Our most advanced product candidate based on SNP technology is OCS-01, which recently completed a Phase 2 study in DME. This study is the first proof-of-concept of a topical drug effect on a chronic retinal disease and is also a successful proof-of-concept for the SNP formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants.
OCS-01 is also in Phase 2 clinical development for Pain and Inflammation following ocular surgery.